VEGFA and hepatocellular carcinoma: In the IMbrave150 study [1], the combination of atezolizumab (an antibody against programmed cell death ligand) and bevacizumab (an antibody against vascular endothelial growth factor A) (Atz/Bev) in patients with advanced hepatocellular carcinoma (HCC) significantly prolonged overall survival (OS) and progression-free survival (PFS) compared with sorafenib [2], the standard of care.